For Research Use Only. Not for human consumption. The following summarizes published preclinical literature for laboratory research purposes only.
What It Is
KPV is a tripeptide composed of the amino acid sequence Lysine-Proline-Valine. It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), specifically the α-MSH(11–13) region, and is classified in the research literature as a melanocortin-derived peptide (Inflammatory Bowel Diseases, 2008, PMID 18092346). As one of the smallest bioactive peptide fragments studied in the anti-inflammatory literature, KPV retains reported activity from its parent hormone despite its minimal three-residue structure.
Summary of Published Preclinical Research
The central published study on KPV, appearing in Inflammatory Bowel Diseases (2008), characterized its activity across two well-characterized murine models of intestinal inflammation: dextran sodium sulfate (DSS)-induced colitis and CD45RB(hi) T-cell transfer colitis (PMID 18092346). In the DSS-colitis model, mice treated with KPV showed earlier recovery and significantly stronger regain of body weight compared to untreated controls. Histological scoring showed significantly reduced inflammatory cell infiltrates in colonic tissue, corroborated by a significant reduction in myeloperoxidase (MPO) activity — an enzyme marker associated with neutrophil accumulation and tissue inflammation. In the transfer-colitis model, KPV treatment similarly produced recovery, body-weight regain, and reduced histological inflammation. Notably, the study also tested KPV in mice expressing a non-functional melanocortin-1 receptor (MC1R-null mice); KPV treatment rescued all treated animals from DSS-colitis-induced mortality in this receptor-deficient group, indicating that at least part of KPV’s anti-inflammatory activity in this model occurs independently of MC1R signaling.
This murine colitis dataset positions KPV within a broader research area examining melanocortin system peptides (including full-length α-MSH) for modulating gut inflammation, neutrophil activity, and cytokine-driven tissue damage in in-vivo and cell-culture inflammation models.
Proposed Mechanism of Action
The 2008 study’s authors propose that KPV’s anti-inflammatory activity is mediated in part through melanocortin receptor pathways, given α-MSH’s known interaction with melanocortin receptors (MC1R being the most studied in skin and immune contexts). However, the rescue of MC1R-null mice from colitis mortality in the same study indicates a receptor-independent component to KPV’s observed effects, suggesting additional, not-yet-fully-characterized intracellular or extracellular pathways may be involved in suppressing myeloperoxidase-linked neutrophil activity and inflammatory infiltration. Because KPV is such a minimal peptide fragment, ongoing structure-activity research continues to probe how its three-residue sequence interacts with immune cell signaling relative to the full α-MSH parent hormone.
Research Use Only / Handling Note
Supplied as a lyophilized powder for laboratory and in-vitro research use only. Not for human or animal consumption; not a drug, supplement, or cosmetic product.